Celularity Inc. Faces Challenges and Plans to Appeal Nasdaq Notice
In a recent development, Celularity Inc. (NASDAQ: CELU), a pioneering regenerative medicine company, has received a formal notification from Nasdaq regarding its stock listing. This notice, delivered by the Listing Qualifications department, indicates potential delisting due to the company’s delay in filing certain financial reports. However, the company’s common stock and warrants continue to be traded on the Nasdaq Capital Market under the symbols 'CELU' and 'CELUW'.
Understanding the Nasdaq Delisting Notice
On October 16, the notice indicated that Celularity could face delisting because it failed to meet the required timeline for submitting Forms 10-Q for two reporting periods. Despite this development, the company is taking proactive steps to maintain its listing on the exchange. It plans to appeal the decision and has until October 24 to request a hearing with the Nasdaq Hearings Panel. This hearing will serve as a platform for Celularity to present its compliance plan and, if necessary, seek a temporary suspension of the delisting.
Commitment to Compliance
Celularity Inc. is dedicated to regaining compliance with Nasdaq’s listing requirements. The company has successfully filed its annual report (Form 10-K) for the fiscal year 2023. Alongside this, the company recently filed its first quarter 2024 report on October 16 and is aiming to submit its second quarter 2024 Form 10-Q soon.
Financial Challenges and Future Outlook
Robert J. Hariri, MD, PhD, Chairman and CEO of Celularity, discussed the substantial financial challenges faced by the company. He clarified that the delays in filing were not due to accounting irregularities but were instead linked to liquidity constraints. Dr. Hariri expressed confidence in the future, especially following the recent acquisition of the Rebound™ product, which is expected to bolster the company’s financial stability.
About Celularity Inc.
Celularity Inc. specializes in developing and commercializing advanced regenerative therapies using placental-derived technologies. The company focuses on creating innovative therapeutic solutions to combat aging-related diseases, cancer, and immune disorders. Its approach utilizes a variety of cutting-edge cell therapies, including engineered T-cells and natural killer cells derived from the postpartum placenta.
The Path Forward
Celularity’s management is adeptly working with their auditors to ensure timely filings moving forward. They remain committed to transparency and communication with shareholders and stakeholders amidst these challenges. Regular updates will be provided, reflecting any shifts in the company’s compliance status or operational activities.
Frequently Asked Questions
What is the main reason for Celularity Inc.’s Nasdaq notice?
Celularity Inc. received a Nasdaq notice due to its failure to timely file Forms 10-Q for specific periods, potentially risking its listing status.
How does Celularity plan to respond to the Nasdaq delisting notice?
The company intends to appeal the Nasdaq decision and will present a plan during a hearing to demonstrate its path towards compliance.
What recent steps has Celularity taken to improve its financial situation?
Celularity announced the acquisition of the Rebound™ product, which is expected to enhance its cash position and operational stability.
What types of therapies does Celularity focus on?
Celularity focuses on placental-derived cell therapies targeting aging-related diseases, cancer, and immune disorders using advanced biomaterials and cell technologies.
Will Celularity provide updates on its compliance status?
Yes, the company has committed to transparently updating its stakeholders on its compliance efforts and operational developments regularly.
